Mineralys Therapeutics (NASDAQ:MLYS) Releases Quarterly Earnings Results, Misses Estimates By $0.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) announced its quarterly earnings data on Monday. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30), Zacks reports. During the same quarter last year, the company earned ($0.57) EPS.

Mineralys Therapeutics Stock Down 1.3 %

Shares of Mineralys Therapeutics stock traded down $0.18 during trading on Wednesday, hitting $13.20. 14,337 shares of the stock were exchanged, compared to its average volume of 178,849. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $16.91. The stock’s fifty day moving average is $12.95 and its 200 day moving average is $12.64.

Insider Activity at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at $3,214,108.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares in the company, valued at $3,214,108.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jon Congleton sold 15,271 shares of the firm’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.52, for a total transaction of $206,463.92. Following the transaction, the chief executive officer now directly owns 895,941 shares in the company, valued at approximately $12,113,122.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,510 shares of company stock worth $735,431 in the last ninety days. 33.24% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a report on Tuesday.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.